{"nctId":"NCT00547898","briefTitle":"Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea","startDateStruct":{"date":"2007-10"},"conditions":["HIV Associated Diarrhea"],"count":374,"armGroups":[{"label":"Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo"]},{"label":"Crofelemer 125 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Crofelemer 125 mg"]},{"label":"Crofelemer 250 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Crofelemer 250 mg"]},{"label":"Crofelemer 500 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Crofelemer 500 mg"]}],"interventions":[{"name":"Crofelemer 125 mg","otherNames":[]},{"name":"Crofelemer 250 mg","otherNames":[]},{"name":"Crofelemer 500 mg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* History of HIV-1 infection confirmed by standard serological tests\n* Stable medical regimen for treatment of HIV disease and associated conditions for at least 4 weeks prior to screening\n* Patient-reported history of diarrhea, defined as either persistently loose stools despite regular ADM use, or one or more watery bowel movements per day without regular ADM use, of at least 1 month duration\n* Colonoscopy within the past 5 years if â‰¥ 50 years of age.\n\nExclusion Criteria:\n\n* Pregnancy or breast-feeding\n* Current or past gastrointestinal (GI) medical or surgical conditions\n* Use of certain opiate pain medication within 2 weeks of screening\n* Use of an antibiotic within 2 weeks prior to screening, with the exception of stable antibiotic therapy for prophylactic treatment of infection or an HIV-associated condition\n* CD4 counts \\< 100 cells/mm3\n* Previous randomization into this study, or into any other crofelemer study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Primary Efficacy Outcome is Count of Participants With Two or Less Watery Bowel Movements Per Week During at Least Two Weeks of the Treatment Phase of the Optimal Dose of Crofelemer Compared to Placebo","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Experiencing Relief of Diarrhea","description":"Relief of diarrhea was defined as two or less watery bowel movements per week during at least two weeks of the treatment phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":137},"commonTop":[]}}}